Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

EDARAVONE

EDARAVONE

Standard Dose
30MG/100ML (0.3MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview EDARAVONE is listed in Drugs@FDA under application 218354 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient EDARAVONE Form and strength SOLUTION;INTRAVENOUS - 30MG/100ML (0.3MG/ML) Sponsor LONG GROVE PHARMS Submission history Latest submission status date: 2024-05-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview EDARAVONE is listed in Drugs@FDA under application 218354 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient EDARAVONE Form and strength SOLUTION;INTRAVENOUS - 30MG/100ML (0.3MG/ML) Sponsor LONG GROVE PHARMS Submission history Latest submission status date: 2024-05-06 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.